S&CO Inc. Makes New Investment in United Therapeutics Corporation $UTHR

S&CO Inc. purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,431 shares of the biotechnology company’s stock, valued at approximately $775,000.

Other hedge funds have also recently made changes to their positions in the company. Wellington Management Group LLP raised its position in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Norges Bank purchased a new position in United Therapeutics during the fourth quarter worth about $293,418,000. Avoro Capital Advisors LLC grew its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Janus Henderson Group PLC grew its position in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after acquiring an additional 295,221 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

NASDAQ UTHR opened at $499.73 on Monday. The stock’s 50-day simple moving average is $535.95 and its two-hundred day simple moving average is $536.15. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The company has a market capitalization of $21.43 billion, a price-to-earnings ratio of 17.88, a PEG ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $6.41 EPS. On average, equities analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $515.03, for a total value of $4,892,785.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $167,097,878.29. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $23,356,182.60. The trade was a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 443,075 shares of company stock valued at $241,508,744 in the last 90 days. 8.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.